Acadia Pharmaceuticals (ACAD) Operating Margin (2010 - 2026)
Acadia Pharmaceuticals' quarterly Operating Margin came in at 1.72% in Q1 2026, down 962.0% year-on-year from 0.2% in Q1 2025, and up 91.58% quarter-over-quarter from 20.46% in Q4 2025.
Acadia Pharmaceuticals has reported Operating Margin for 17 years, with the latest figure at 1.72% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 962.0% year-over-year to 1.72%; the trailing twelve-month figure through Mar 2026 stood at 0.49% (down 2308.0% YoY), and the FY2025 full-year result was 2.74%, down 2136.0% from the prior year.
- Operating Margin for Q1 2026 stood at 1.72%, up from 20.46% in the prior quarter.
- The five-year high for Operating Margin was 59.13% in Q4 2024, with the low at 97.88% in Q1 2022.
- Average Operating Margin over 5 years is 7.84%, with a median of 1.84% recorded in 2023.
- Year-over-year, Operating Margin sank 10304 bps in 2022 and surged 5264 bps in 2023.
- Tracing ACAD's Operating Margin over 5 years: stood at 33.75% in 2022, then soared by 145 bps to 15.12% in 2023, then jumped by 291 bps to 59.13% in 2024, then sank by 135 bps to 20.46% in 2025, then surged by 92 bps to 1.72% in 2026.
- The last three Operating Margin figures came in at 1.72% (Q1 2026), 20.46% (Q4 2025), and 12.83% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | -1.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.72% |
| Dec 31, 2025 | -20.46% |
| Sep 30, 2025 | 12.83% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.90% |
| Dec 31, 2024 | 59.13% |
| Sep 30, 2024 | 12.64% |
| Jun 30, 2024 | 12.58% |
| Mar 31, 2024 | 7.39% |
| Dec 31, 2023 | 15.12% |
| Sep 30, 2023 | -27.29% |
| Jun 30, 2023 | 1.84% |
| Mar 31, 2023 | -45.23% |
| Dec 31, 2022 | -33.75% |
| Sep 30, 2022 | -23.61% |
| Jun 30, 2022 | -25.01% |
| Mar 31, 2022 | -97.88% |
| Dec 31, 2021 | 69.29% |
| Sep 30, 2021 | -11.63% |
| Jun 30, 2021 | -37.93% |
| Mar 31, 2021 | -62.66% |
| Dec 31, 2020 | 132.57% |
| Sep 30, 2020 | -71.24% |
| Jun 30, 2020 | -39.97% |
| Mar 31, 2020 | -99.39% |
| Dec 31, 2019 | -57.36% |
| Sep 30, 2019 | -48.02% |
| Jun 30, 2019 | -68.61% |
| Mar 31, 2019 | -139.19% |
| Dec 31, 2018 | 216.45% |
| Sep 30, 2018 | -105.09% |
| Jun 30, 2018 | -112.30% |
| Mar 31, 2018 | -112.18% |
| Dec 31, 2017 | -160.71% |
| Sep 30, 2017 | -184.51% |
| Jun 30, 2017 | -223.25% |
| Mar 31, 2017 | -580.41% |
| Dec 31, 2016 | -654.00% |
| Sep 30, 2016 | -1,374.32% |
| Jun 30, 2016 | -74,147.42% |
| Mar 31, 2016 | -1,256,550.00% |
| Dec 31, 2015 | 372,047.06% |
| Sep 30, 2015 | -99,994.87% |
| Jun 30, 2015 | -3,949,700.00% |
| Mar 31, 2015 | -1,013,800.00% |
| Dec 31, 2014 | 70,712.77% |
| Sep 30, 2014 | -166,626.67% |
| Jun 30, 2014 | -77,582.14% |
| Mar 31, 2014 | -59,860.00% |
| Dec 31, 2013 | 35,759.46% |
| Sep 30, 2013 | -4,504.58% |
| Jun 30, 2013 | -2,030.38% |
| Mar 31, 2013 | -1,478.18% |
| Dec 31, 2012 | -1,794.47% |
| Sep 30, 2012 | -69.21% |
| Jun 30, 2012 | -906.34% |
| Mar 31, 2012 | -1,384.67% |
| Dec 31, 2011 | -903.74% |
| Sep 30, 2011 | -872.09% |
| Jun 30, 2011 | -1,431.30% |
| Mar 31, 2011 | -1,347.36% |
| Dec 31, 2010 | 83.95% |
| Sep 30, 2010 | -184.35% |